In Vitro Drug Metabolism

Thiol Conjugation
  • Wei Tang
  • Randy R. Miller
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

From a pharmaceutical research point of view, it seems reasonable in the early phase of discovery to eliminate those drug candidates that are subject to bioactivation to electrophilic intermediates. Although rarely detectable per se, the structures of these intermediates often can be deduced by analysis of the corresponding glutathione or N-acetylcysteine conjugates. A practical approach in this regard, therefore, is to screen drug candidates in vitro for the formation of reactive metabolites via incubations with liver microsomes or hepatocytes prepared from preclinical species or humans. These incubations are normally carried out at 37°C for a period of time in the presence of glutathione or N-acetylcysteine, followed by solid-phase extraction of the reaction mixture. The resulting samples are subject to reversed-phase chromatography. Further on-line detection and identification of thiol conjugates by mass spectrometry are performed in a stepwise manner from neutral loss and/or parent ion scans to multiple-stage mass fragmentations. This would eventually lead to elucidating the structures of reactive intermediates, from which the thiol conjugates result. The experiments require minimal sample preparation and method development and often afford ample structural information on the analytes.

Key Words

Glutathione N-acetylcysteine thiol conjugation drug metabolism bioactivation reactive metabolites HPLC mass spectrometry 

References

  1. 1.
    DeLeve, L. D. and Kaplowitz, N. (1991) Glutathione metabolism and its role in hepatotoxicity. Pharm. Ther. 52, 287–305.CrossRefGoogle Scholar
  2. 2.
    Lu, S. C. (1999) Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J. 13, 1169–1183.PubMedGoogle Scholar
  3. 3.
    Smith, C. V., Jones, D. P., Guenthner, T. M., Lash, L. H., and Lauterburg, B. H. (1996) Compartmentation of glutathione: implications for the study of toxicity and disease. Toxicol. Appl. Pharmacol. 140, 1–12.PubMedCrossRefGoogle Scholar
  4. 4.
    Reed, D. J. (1986) Regulation of reductive processes by glutathione. Biochem. Pharmacol. 35, 7–13.PubMedCrossRefGoogle Scholar
  5. 5.
    Orrenius, S. and Moldeus, P. (1984) The multiple roles of glutathione in drug metabolism. Trends Pharmacol. Sci. 5, 432–435.CrossRefGoogle Scholar
  6. 6.
    Cohen, S. D., Pumford, N. R., Khairallah, E. A., Boekelheide, K., Pohl, L. R., Amouzadeh, H. R., et al. (1997) Selective protein covalent binding and target organ toxicity. Toxicol. Appl. Pharmacol. 143, 1–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Uetrecht, J. P. (1999) New concept in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem. Res. Toxicol. 12, 387–395.PubMedCrossRefGoogle Scholar
  8. 8.
    Chasseaud, L. F. (1979) The role of glutathione and glutathione-S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res. 29, 175–274.PubMedCrossRefGoogle Scholar
  9. 9.
    Ketterer, B. and Mulder, G. (1990) Glutathione conjugation, in Conjugation Reaction in Drug Metabolism (Mulder, G. J., ed.), Taylor & Francis, New York, pp. 307–364.Google Scholar
  10. 10.
    Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1992) Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br. J. Clin. Pharmacol. 34, 377–395.PubMedGoogle Scholar
  11. 11.
    Park, B. K., Pirmohamed, M., and Kitteringham, N. R. (1998) Role of drug disposition in drug hypersensitivity: a chemical, molecular, and clinical perspective. Chem. Res. Toxicol. 11, 969–988.PubMedCrossRefGoogle Scholar
  12. 12.
    Baillie, T. A. and Kassahun, K. (2001) Biological reactive intermediates in drug discovery and development: a perspective from the pharmaceutical industry, in Biological Reactive Intermediates VI: Chemical and Biological Mechanisms Insusceptibility to and Prevention of Environmental Diseases (Dansette, P. M., Snyder, R., Delaforge, M., Gibson, G. G., Greim, H., Jollow, D. J., et al., eds.), Kluwer Academic/Plenum, New York, pp. 45–51.Google Scholar
  13. 13.
    Baillie, T. A. and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319–325.PubMedCrossRefGoogle Scholar
  14. 14.
    Nikolic, D., Fan, P. W., Bolton, J. L., and van Breemen, R. B. (1999) Screening for xenobiotic electrophilic metabolites using pulsed ultrafiltration-mass spectrometry. Combin. Chem. High Through. Screen. 2, 165–175.Google Scholar
  15. 15.
    Raucy, J. L. and Lasker, J. M. (1991) Isolation of P450 enzymes from human liver. Meth. Enzymol. 206, 557–587.Google Scholar
  16. 16.
    Pang, J.-M., Zaleski, J., and Kauffman, F. C. (1997) Toxicity of allyl alcohol in primary cultures of freshly isolated and cryopreserved hepatocytes maintained on hydrated collagen gels. Toxicol. Appl. Pharmacol. 142, 87–94.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen, Q., Ngui, J. S., Doss, G. A., Wang, R. W., Cai, X., DiNinno, F. P., et al. (2002) Cytochrome P450 3A4-mediated bioactivation of raloxifene: irreversible enzyme inhibition and thiol adduct formation. Chem. Res. Toxicol. 15, 907–914.PubMedCrossRefGoogle Scholar
  18. 18.
    Tang, W. and Abbott, F. S. (1996) Bioactivation of a toxic metabolite of valproic acid, (E)-2-propyl2,4-pentadienoic acid, via glucuronidation: LC/MS/MS characterization of the GSH-glucuronide diconjugates. Chem. Res. Toxicol. 9, 517–526.PubMedCrossRefGoogle Scholar
  19. 19.
    Samuel, K., Yin, W., Stearns, R. A., Tang, Y. S., Chaudhary, A. G., Jewell, J. P., et al. (2003) Addressing the metabolic activation potential of new leads in drug discovery: a case study using ion trap mass spectrometry and tritium labeling techniques. J. Mass Spectrom. 38, 211–221.PubMedCrossRefGoogle Scholar
  20. 20.
    Alt, C. and Eyer, P. (1998) Ring addition of the α-amino group of glutathione increases the reactivity of benzoquinone thioethers. Chem. Res. Toxicol. 11, 1223–1233.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2004

Authors and Affiliations

  • Wei Tang
    • 1
  • Randy R. Miller
    • 1
  1. 1.Department of Drug MetabolismMerck Research LaboratoriesRahway

Personalised recommendations